On June 5, 2023 , the Biotechnology Innovation Organization (BIO) announced its new Executive Committee Directors during the 2023 BIO International Convention taking place in Boston from June 5-8, 2023.
Among the newly elected members is the new chair, Dr. Ted W. Love, who will be serving a two-year term until 2025.
Who is Dr. Love?
Dr. Ted Love is a well-known industry leader who started his career with nearly a decade of experience as a physician. Dr. Love has spent over 20 years in management positions and has spent much of his career dedicating his efforts to tackling the persistent healthcare inequities that impact the sickle cell disease community, while also spearheading the advancement of therapies for this marginalized group of patients.
Dr. Love is the former President and CEO of Global Blood Therapeutics, a biopharmaceutical company dedicated to the development of life-changing treatments for underserved communities. Global Blood Therapeutics was purchased by Pfizer last year.
Dr. Love has been actively engaged with BIO for an extended period, serving as a board director and, more recently, as the Chair of the Emerging Companies Section Governing Board for the past four years. Additionally, he has fulfilled the role of Vice Chair for BIO’s Health Section Governing Board.
Dr. Love stated, “I am excited to lead BIO and the individuals elected today as we usher in a new era for the biotechnology industry. Throughout my career, I’ve seen what it means when people cannot access the care they need. Greater diversity in our industry will help drive innovation forward, especially for segments of our society who lack access to critical medical treatments, adequate nutrition, and a clean environment.”
“BIO is thrilled to welcome Ted as our new Board Chair,” says Rachel King, BIO President and CEO. “Ted is a proven innovator who has developed and brought critical therapies to market. He embodies the industry’s mission to advance innovation, increase access to novel treatments, and build an inclusive workforce to reach our most underserved patient communities.”
Additional Board announcements
Elizabeth Lewis, Head of Global Oncology Patient Value, Policy, and Access at Takeda Oncology, was reelected Associate Vice Chair and Secretary of the BIO Board.
Bradford Zakes, President and CEO of Cerevast Medical, Inc., was reelected Board Treasurer.
Paul Hastings, who has served as BIO Chair since 2021, shared his thoughts on what’s been accomplished over the past two years, and the work remaining.